Objective. To evaluate the efficacy and safety of ustekinumab in 3 randomized, placebo-controlled studies in patients with axial spondyloarthritis (SpA). Studies 1 and 2 included patients with radiographic axial SpA (anti-tumor necrosis factor [anti-TNF]-naive patients and patients with inadequate response or intolerance to anti-TNF, respectively); study 3 patients had nonradiographic axial SpA.
INTRODUCTION
Axial spondyloarthritis (SpA) is an immune-mediated systemic chronic inflammatory arthritis involving the axial skeleton that may involve peripheral joints. It is characterized by chronic inflammatory back pain (IBP), which typically has an insidious onset and improves with exercise but not rest (1) . Axial SpA also manifests with sacroiliitis, spondylitis, and enthesitis, which may lead to ankylosis (1) . Extraarticular manifestations include uveitis, inflammatory bowel disease, and psoriasis. Chronic inflamma-tion in axial SpA can lead to bone loss and structural damage, including erosions and ankylosis of the sacroiliac (SI) joints and spine. This damage may lead to postural changes and mobility restriction resulting in functional impairment and decreased health-related quality of life (2, 3) . Patients with axial SpA include those with nonradiographic axial SpA (before the occurrence of definitive structural damage to the SI joints on radiography) and those with radiographic axial SpA. Patients with radiographic axial SpA and those with ankylosing spondylitis (AS) belong to the same subgroup, with slight differences in the exact definitions (4, 5) (also see below).
Nonsteroidal antiinflammatory drugs (NSAIDs) are used to treat symptoms of axial SpA in many patients; however, conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) or systemic glucocorticoids are ineffective for the axial component. Anti-tumor necrosis factor (anti-TNF) therapies are approved for use in AS globally and for nonradiographic axial SpA in many countries. More recently, a monoclonal antibody that inhibits interleukin-17A (IL-17A) was approved to treat adults with AS (6) . Although these agents show efficacy in many patients with axial SpA, some patients do not respond adequately; thus, there is a need to target other mechanisms of action (7, 8) .
Axial SpA may be triggered by a combination of genetic and environmental factors. Axial SpA is strongly associated with HLA-B27, misfolding and accumulation of which can activate up-regulation of IL-23 production and induction of the Th17 axis (9) . The IL-23/Th17 axis has gained attention recently as a possible inflammatory pathway for axial SpA (10, 11) , which suggests that IL-23 is involved in disease pathogenesis (12, 13) .
Ustekinumab, a human monoclonal antibody targeting the IL-12/23 p40 subunit, is effective in treating active psoriasis (14, 15 ), Crohn's disease (16) , and psoriatic arthritis (PsA) (17) (18) (19) (20) , including inhibition of radiographic progression, and has been shown to improve spondylitis symptoms in a subgroup of PsA patients with physician-reported spondylitis (21) .
A small, open-label study suggested preliminary efficacy of ustekinumab for the treatment of AS (8) . Twenty patients with active AS received 90 mg ustekinumab at weeks 0, 4, and 16. Clinically meaningful improvements were noted at week 24, and significant improvements in inflammation were observed in magnetic resonance imaging (MRI) parameters (8) . In the 3 randomized, placebo-controlled studies reported herein, efficacy and safety of ustekinumab were evaluated in patients with active axial SpA (radiographic or nonradiographic).
PATIENTS AND METHODS
Study design. Two parallel, phase III, multicenter, randomized, double-blind, placebo-controlled studies evaluated treatment with ustekinumab at 45 mg and 90 mg in patients with active radiographic axial SpA who had an inadequate response to or were intolerant of NSAIDs and who were naive to anti-TNF therapy (study 1) or who were refractory (defined as having an inadequate response or intolerance) to a single anti-TNF agent (study 2). A third study (study 3) evaluated patients with active nonradiographic axial SpA who had an inadequate response to or were intolerant of NSAIDs and who could have been exposed to a single anti-TNF agent. These studies were conducted in accordance with the principles of the Declaration of Helsinki. Each patient gave written informed consent. An independent data monitoring committee regularly reviewed unblinded safety data. A list of investigators who randomized patients in the 3 trials is provided in Appendix A.
In all 3 studies, patients were randomly assigned (1:1:1) to receive subcutaneous (SC) administration of ustekinumab at 45 mg or 90 mg at weeks 0, 4, and 16 and then every 12 weeks or to receive placebo at weeks 0, 4, and 16. Placebo-treated patients were rerandomized at week 24 to receive ustekinumab at 45 mg or 90 mg at weeks 24 and 28 and then every 12 weeks. For studies 1 and 2, at week 16, patients in all 3 treatment groups who qualified for early escape (those with <10% improvement from baseline in both total back pain and morning stiffness measures at both week 12 and week 16) received open-label golimumab at 50 mg SC at week 16 and every 4 weeks thereafter through week 52. Final safety evaluations were to be performed at week 64 (study 2) and week 112 (study 1).
In study 3, patients in the placebo group who met early escape criteria were to be rerandomized at week 16 in a blinded manner to SC ustekinumab at 45 mg or 90 mg at weeks 16, 20, 28 , and every 12 weeks thereafter through week 52. At week 24, all remaining placebo-treated patients crossed over to ustekinumab at either 45 mg or 90 mg at weeks 24 and 28, then every 12 weeks. All patients with inactive disease at both week 40 and week 52 were to be rerandomized at week 52 to either keep receiving ustekinumab or switch to placebo. The study was to continue to week 100. Inclusion/exclusion criteria. A central reader assessed the presence or absence of radiographic sacroiliitis (according to the modified New York criteria for AS) for all 3 studies and the presence or absence of the ASAS/Outcome Measures in Rheumatology MRI group criteria for defining sacroiliitis by MRI (22) for study 3. In studies 1 and 2, eligible adult patients (age ≥18 years) fulfilled the modified New York criteria for AS (4). They also had active disease, defined as a Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) (23) ≥4 and a visual analog scale score for total back pain ≥4 at screening and at baseline as well as a high-sensitivity C-reactive protein (hsCRP) level ≥0.3 mg/dl at screening. They also had an inadequate response to or intolerance of a single anti-TNF agent (patients in study 2) but were otherwise naive to biologic agents. Concomitant NSAIDs, glucocorticoids (≤10 mg prednisone equivalent per day), or the csDMARDs methotrexate, sulfasalazine, or hydroxychloroquine were permitted; however, doses of NSAIDs and glucocorticoids were required to be stable for ≥2 weeks prior to baseline, and doses of csDMARDs were required to be stable for ≥4 weeks prior to baseline. Patients with complete ankylosis of the spine (assessed locally) were limited to 10% of the study population. Key exclusion criteria included other inflammatory diseases, active infection, uncontrolled concomitant diseases, and pregna ncy.
For study 3, adults (ages 18-50 years) were eligible if they had active nonradiographic axial SpA that fulfilled the ASAS criteria for axial SpA (5) (back pain for ≥3 months and disease onset by age 45 years as well as evidence of active acute inflammation on MRI and ≥1 feature of SpA or HLA-B27 positive and ≥2 features of SpA) without radiographic sacroiliitis according to the modified New York criteria for AS (4) . Patients without a positive MRI of the SI joints according to the ASAS definition required an elevated hsCRP ≥0.6 mg/dl at screening. All patients had active disease as defined in studies 1 and 2; patients could have been exposed to 1 anti-TNF agent.
Outcome assessments. Primary and major secondary end points. The primary end point was the proportion of patients who met the ASAS criteria for 40% improvement in disease activity (achieved an ASAS40 response) at week 24 in studies 1 and 2 and the proportion of patients who achieved an ASAS20 response at week 24 in study 3 (24) (25) (26) . Major secondary end points were the proportions of patients who achieved an ASAS20 response (studies 1 and 2) and an ASAS40 response (study 3), the proportion of patients with 50% improvement in the BASDAI (a BASDAI50 response), change from baseline in the Bath Ankylosing Spondylitis Functional Index (BASFI) (27) , and the proportion of patients with inactive disease according to the Ankylosing Spondylitis Disease Activity Score using the CRP level (an ASDAS-CRP score <1.3) (28) .
Additional secondary end points. Additional secondary end points included changes from baseline in hsCRP level and ASDAS-CRP. A subset of patients from study 1 underwent MRI for spinal inflammation assessment using the Berlin MRI scoring method (29) (baseline and week 24, averaged scores of 2 central readers). During the double-blind period of studies 1, 2, and 3, serum samples were collected to evaluate ustekinumab pharmacokinetics, antibodies to ustekinumab, and/or biomarkers. Evaluation of the presence of antibodies to ustekinumab used a drug-tolerant enzyme chemiluminescent immunoassay in samples from patients who received ≥1 administration of ustekinumab and had ≥1 postadministration sample available.
Serum biomarkers were assayed using a Singulex system Cisbio human kit (S100 calcium binding protein A12). Biomarkers were evaluated in a subset of patients from studies 1 and 2, and clinical responders were oversampled versus the overall study population to increase statistical power for testing clinical response associations.
Due to discontinuation of the study, most secondary end points were only summarized for samples from study 1. Safety outcomes included the proportions of patients experiencing treatment-emergent adverse events (AEs) and serious AEs (SAEs) from baseline to the end of the study, along with clinical laboratory testing.
Statistical analysis. Sample sizes of all 3 studies were chosen to achieve 90% power to detect treatment differences between ustekinumab and placebo for the primary end point at a 2-sided significance level of 0.05. Sample size calculations were based on results from a ustekinumab investigator-initiated study and a certolizumab pegol axial SpA study (30) . For study 1, the planned sample size calculation was based on anticipating an ASAS40 response of 40% in the ustekinumab group and 20% in the placebo group with n = 109 for each group. For study 2, the planned sample size calculation was based on an ASAS40 response of 30% in the ustekinumab group and 15% in the placebo group with n = 161 for each group. For study 3, the planned sample size calculation was based on the ASAS20 responses in the ustekinumab groups versus the placebo groups: 50% versus 35% in the anti-TNF inadequate responder group and 60% versus 40% in the other group (anti-TNF-naive and anti-TNF-experienced patients) with n = 130 for each group. It was preplanned to determine continuation of studies 2 and 3 based on the study 1 results at week 24.
For study 1, efficacy analyses were performed using the modified intent-to-treat (ITT) population, which included all patients who received ≥1 dose of study medication. Primary and major secondary end points were analyzed sequentially to control for multiplicity and were contingent on the success of the primary analysis.
Because studies 2 and 3 were terminated early based on study 1 results, a modified full analysis set was defined that included patients who were anticipated to have reached the week 24 visit. Additionally, only selected efficacy analyses through week 24, including primary and major secondary end points, were performed.
The following analysis rules were applied to all 3 studies. For dichotomous responder-type end points, patients with missing postbaseline responses or those who met treatment failure criteria (initiating new therapies or increasing concomitant medication doses for axial SpA or discontinuing study treatment due to lack of efficacy) were classified as nonresponders. Patients who entered early escape at week 16 were considered nonresponders for dichotomous end points at weeks 20 and 24; measurement values at those weeks were set as missing for continuous end points. The Cochran-Mantel-Haenszel chi-square test was used to compare categorical variables. Generally, continuous parameters were compared using a repeated measures mixed model analysis with treatment group, strata, baseline value, visit week, and an interaction of treatment with visit week as independent variables. All statistical testing was performed at a 2-sided alpha level of 0.05. Patients who received ≥1 dose of study medication were included in safety analyses.
Serum proteins for biomarker analysis were assayed at weeks 0, 4, and 16 from a subset of patients from study 1 (n = 105 in ustekinumab treatment arms [pooled dose groups], n = 45 placebo-treated patients, n = 40 demographically matched healthy controls) and study 2 (n = 41 in ustekinumab treatment arms [pooled dose groups], n = 29 demographically matched healthy controls), with the exception of Th17 analytes, which were measured only at baseline in a small subset of patients (n = 29 randomized to receive ustekinumab, n = 29 healthy controls). Significance was defined by P < 0.05 and absolute value of either fold change >1.2 or Pearson's correlation coefficient (r) of >0.25.
RESULTS
Patient disposition. Data were collected from July 2015 to September 2017. Patients were randomized at 58 sites in 7 countries for study 1, 114 sites in 19 countries for study 2, and 93 sites in 14 countries for study 3. The scheduled week 24 database lock and review of results for study 1 showed that the primary and major secondary end points were not met for either ustekinumab dose. As a result, the sponsor discontinued all 3 studies in May 2017. Patient's global assessment of disease activity, 0-10-cm VAS 7.5 ± 1.6 7.5 ± 1.6 7.6 ± 1.4 7.5 ± 1.5 7.5 ± 1.5
Total back pain, 0-10-cm VAS 7.6 ± 1.5 7.6 ± 1.4 7.7 ± 1.4 7.6 ± 1.4 7.6 ± 1.4
BASFI, 0-10 6.6 ± 2.2 6.8 ± 1.9 7.0 ± 1.6 6.9 ± 1.8 6.8 ± 1.9
Inflammation score § 7.5 ± 1.7 7.7 ± 1.5 7.7 ± 1.5 7.7 ± 1.5 7.6 ± 1.6
hsCRP, mg/dl ¶ 2. BASDAI, 0-10 7.5 ± 1.3 7.6 ± 1.4 7.5 ± 1.3 7.6 ± 1. Total back pain, 0-10-cm VAS 7.8 ± 1.6 7.7 ± 1.5 7.8 ± 1.4 7.7 ± 1.4 7.8 ± 1.5 BASFI, 0-10 7.2 ± 1.6 6.9 ± 2.0 6.9 ± 1.7 6.9 ± 1.8 7.0 ± 1.8
Inflammation score § 7.8 ± 1.8 7.8 ± 1.9 7.8 ± 1. A total of 2,062 patients were screened, of whom 1,018 were randomized and 1,017 were treated (Figure 1 ; also see Supplementary Figures 1 and 2 , available on the Arthritis & Rheumatology web site at http://onlinelibrary.wiley.com/doi/10.1002/ art.40728/abstract). Safety data were evaluated for treated patients, and all 346 treated patients were evaluable for efficacy in study 1. Efficacy was evaluated in a subset of the modified ITT population for study 2 (n = 213, 44.1% of planned sample size) and study 3 (n = 250, 64.1% of planned sample size) as a result of sponsor-initiated early study termination.
Overall, in studies 1 and 2, respectively, 85% and 83% of patients were male, 73% and 79% were white, the mean age was 39.0 and 41.2 years, and the mean duration of IBP was 10.8 and 14.3 years. In study 3 overall, 51% of patients were male, 85% were white, the mean age was 34.3 years, and the mean duration of IBP was 4.5 years. Approximately 12% of patients in study 3 were anti-TNF experienced. Baseline demographics and disease characteristics are shown in Table 1 . All patients in study 1 and study 2 met the modified New York criteria for AS, as specified in the protocol, and 92.8% and 93.7%, respectively, met the ASAS classification criteria for radiographic axial SpA (7.2% and 6.3% had IBP that started at or after age 45 years in study 1 and study 2, respectively, and therefore did not formally fulfill the ASAS axial SpA criteria).
The subset of patients included in the study 1 MRI analysis (n = 104) was primarily male (78%) and white (98%) and had a mean ± SD age of 38.2 ± 11.2 years, a mean ± SD duration of IBP of 10.0 ± 8.4 years, and a mean ± SD hsCRP level of 2.7 ± 2.6 mg/dl. Mean baseline ASAS20/40 response component scores for this subset of patients ranged from 7.2 to 7.9.
Efficacy outcomes. Results for primary and major secondary end points for study 1 are shown in Figure 2 and Table 2 . Those for studies 2 and 3 are shown in Table 2 . In study 1 (patients naive to anti-TNF therapy), the primary end point (an ASAS40 response) and major secondary end points were not achieved. At week 16, early escape criteria were met by 22% of patients in the placebo group, 18% of patients in the ustekinumab 45 mg group, and 12% of patients in the uste kinumab 90 mg group. No patient met treatment failure criteria. The proportions of patients who achieved an ASAS40 response in the ustekinumab 45 mg (31%) and 90 mg (28%) groups and in the placebo group (28%) were not significantly different (Figure 2A) . Neither ustekinumab dose group demonstrated improvement over placebo in achieving an ASAS20 response, a BASDAI50 response, inactive disease according to the ASDAS-CRP (a score <1.3), or mean change from baseline in the BASFI (Figures 2B  and C) . In general, secondary efficacy and health-related quality of life end points did not show meaningful differences between treatment groups. However, modest improvement was noted for the change in hsCRP level from baseline, which was generally greater in both ustekinumab groups than in the placebo group as early as week 4 through week 24. At week 24, mean changes from baseline in hsCRP level were numerically higher in the ASDAS-CRP ‡ 3.8 ± 0.9 3.7 ± 0.9 3.8 ± 0.9 3.8 ± 0.9 3.8 ± 0.9
ASAS components
Patient's global assessment of disease activity, 0-10-cm VAS 7.6 ± 1.6 7.5 ± 1.5 7.5 ± 1.5 7.5 ± 1.5 7.5 ± 1.5
Total back pain, 0-10-cm VAS 7.5 ± 1.6 7.5 ± 1.6 7.6 ± 1.4 7.6 ± 1. ustekinumab-treated groups than in the placebo group (Table 2) . Additionally, in the MRI substudy, the mean change from baseline in the Berlin MRI spine score for patients evaluated at week 24 was −0.6 for the ustekinumab 45 mg group, −1.2 for the ustekinumab 90 mg group, and −0.5 for the placebo group. In study 2 (patients with disease refractory to a single anti-TNF agent), early study discontinuation prohibited valid statistical testing and formulating subsequent clinical conclusions. The proportion of patients with an ASAS40 response (the primary end point) in the ustekinumab 45 mg and 90 mg groups was 19% and 27%, respectively, and 12% in the placebo group. Similar patterns were noted for major secondary end points (Table 2). At week 24, mean changes from baseline in hsCRP level were not numerically higher in the ustekinumab-treated groups than in the placebo group (Table 2 ).
In study 3 (patients with nonradiographic axial SpA), 55% and 49% of patients in the ustekinumab 45 mg and 90 mg groups, respectively, achieved an ASAS20 response (the primary end point) versus 48% in the placebo group. Similar patterns were noted in major secondary end points (Table 2) . At week 24, mean changes from baseline in hsCRP level were numerically higher in the ustekinumab-treated groups than in the placebo group (Table 2) .
Safety. Through the end of week 24, the proportions of patients experiencing AEs in the ustekinumab groups were consistent across treatment groups in all 3 studies (Tables 3 and 4) and similar between the active treatment and placebo groups. No patient died, experienced a serious or opportunistic infection, or presented with malignancy or active tuberculosis. In all 3 studies, <2.0% of ustekinumab-treated patients had an injection site reaction; all were mild in severity.
In study 1, through week 24, 43% of patients in the placebo group and 40% in the combined ustekinumab groups had ≥1 AE. No patient in study 1 discontinued due to AEs through week 24 (Table 3) . During this period, 2 placebo-treated patients reported an SAE (ischemic stroke and vertebrobasilar insufficiency). In the combined ustekinumab groups, 3 patients reported an SAE (subdural hematoma, osteoarthritis, and facial paralysis).
The proportion of patients reporting AEs through week 24 for study 2 (Table 3 ) and study 3 ( Table 4 ) was similar to the proportion in study 1 (Table 3) . In study 2, discontinuation due to an AE through week 24 occurred for 1 placebo-treated patient (back and musculoskeletal pain) and 3 ustekinumab-treated patients (worsening of AS, arthralgia, and back pain). During this period, 3 SAEs were reported in 3 placebo-treated patients (uterine prolapse, back pain, and myocardial ischemia), and 10 SAEs were reported in 7 ustekinumab-treated patients (upper abdominal pain, nausea, vomiting, obesity, uterine polyp, gastrointestinal hemorrhage, cholelithiasis, worsening of AS, rotator cuff syndrome, and cerebrovascular accident). In study 3, 1 ustekinumab-treated patient discontinued due to an AE (pustular psoriasis) through week 24. During this period, SAEs were reported for 2 placebo-treated patients (uveitis and worsening of axial SpA) and 3 ustekinumab-treated patients (inguinal hernia, chronic sinusitis, and ankle fracture).
For all 3 studies, through the end of the study (see Supplementary Tables 1 and 2 , http://onlinelibrary.wiley.com/doi/ Figure 2 . Primary and major secondary end points at week 24 for study 1 (anti-tumor necrosis factor-naive patients with ankylosing spondylitis). A, Primary end point: the proportion of patients who met the Assessment of SpondyloArthritis international Society criteria for 40% improvement in disease activity (achieved an ASAS40 response). B, Major secondary end points: the proportion of patients who achieved an ASAS20 response, the proportion of patients with 50% improvement in the Bath Ankylosing Spondylitis Disease Activity Index (a BASDAI50 response), and the proportion of patients with inactive disease according to the Ankylosing Spondylitis Disease Activity Score using the C-reactive protein level (an ASDAS-CRP score <1.3). C, Mean change from baseline in the Bath Ankylosing Spondylitis Functional Index (BASFI). There were no significant differences between either dose group and the placebo group.
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10.1002/art.40728/abstract), the safety profile was consistent with what was reported through week 24 (Tables 3 and 4) . In study 1, after week 24, an additional 6 ustekinumab-treated patients reported 9 SAEs. In study 2, after week 24, an additional 3 ustekinumab-treated patients reported SAEs. In study 3, after week 24, an additional 7 ustekinumab-treated patients reported SAEs. Serious infections were reported for 2 patients in study 1 and 1 patient in study 3. No patient presented with malignancy or active tuberculosis. In study 1, after week 52, 1 patient (randomized to 45 mg ustekinumab then early escaped to golimumab) was reported to have a fatal SAE of blunt trauma. No deaths were reported for studies 2 or 3.
Pharmacokinetics and immunogenicity.
After administration of ustekinumab at week 0 and week 4 then every 12 weeks in study 1, serum ustekinumab concentrations were dose proportional without evidence of accumulation in ustekinumab concentrations over time, which was similar to prior studies with ustekinumab in PsA. Ustekinumab concentrations were reviewed to confirm that patients received their assigned treatment (ustekinumab or placebo). Given the fixed dosing of ustekinumab, median ustekinumab concentrations were generally higher in the lower body weight quartiles than in the higher body weight quartiles. Patients with lower baseline hsCRP levels had higher median ustekinumab concentrations than those with higher baseline hsCRP levels. Through week 24, median ustekinumab concentrations were lower for ASAS40 nonresponders than for responders after receiving ustekinumab at 45 mg; however, median ustekinumab concentrations were similar between ASAS40 responders and nonresponders for those who received ustekinumab at 90 mg. ASAS20 and ASAS40 response rates were consistent across the 4 trough ustekinumab concentration quartiles.
Antibodies to ustekinumab were detected in 18% of 230 patients through week 24 using a validated drug-tolerant enzyme chemiluminescent immunoassay. Antibody peak titers were generally low, with 26 (11%) of 230 patients found to be positive for neutralizing antibodies. Patients positive for antibodies to ustekinumab had similar ASAS20 responses and higher ASAS40 responses than patients negative for antibodies to ustekinumab. No antibody-positive patients and 1 antibodynegative patient had an injection site reaction through week 24. Due to the early discontinuation, these analyses were not performed for studies 2 and 3. .4) Change from baseline in ASDAS-CRP
Change from baseline in hsCRP, mg/dl
Change from baseline in BASFI −1.9 ± 2.1 (88)
* Except where indicated otherwise, values are the mean ± SD (no. of patients). Anti-TNF = anti-tumor necrosis factor; AS = ankylosing spondylitis; SpA = spondyloarthritis; BASDAI50 response = 50% improvement in the Bath Ankylosing Spondylitis Disease Activity Index; ASDAS-CRP = Ankylosing Spondylitis Disease Activity Score using the C-reactive protein level; hsCRP = high-sensitivity CRP; BASFI = Bath Ankylosing Spondylitis Functional Index. † For studies 1 and 2, 40% improvement in disease activity according to the Assessment of SpondyloArthritis international Society criteria (an ASAS40 response) was the primary end point, and achieving an ASAS20 response was a major secondary end point. For study 3, achieving an ASAS20 response was the primary end point, and achieving an ASAS40 response was a major secondary end point.
Biomarker analysis. In study 1, 10 of 18 analytes tested at baseline were either correlated with disease activity (ASDAS) or were elevated compared with matched healthy controls. However, neither Th17 cytokines (IL-17A, IL-17F, IL-22, and IL-23) nor Th1 cytokines (IFNγ and IL-12p70) were dysregulated at baseline in AS patients compared with healthy controls (see Supplementary Table 3 , http://onlinelibrary.wiley.com/doi/10.1002/ art.40728/abstract). In study 2, overall, there was greater elevation of inflammatory cytokines compared with study 1, including the statistically significant dysregulation of IL-17A, MMP-3, and MMP-9 (but not IL-17F, IFNγ, or IL-12p70), which did not reach statistical significance in study 1. Additionally, a higher fold change of SAA, CRP level, and TNFα was observed in the cohort from study 2. Although overall baseline levels of IL-17A were slightly higher in axial SpA patients enrolled in study 2 compared with healthy controls, there was no association with clinical response in this small sample.
In study 1, ustekinumab treatment had only a relatively minor impact on analytes at weeks 4 and 16, with only MMP-3, SAA, and IL-8 being significantly decreased. The decreases in these 3 analytes were independent of week 16 ASAS20 clinical response. In summary, in these cohorts, up-regulation of acute | 267
inflammatory proteins (and MMPs) was seen, but very modest to no elevation of Th17/Th1 cytokines in the periphery was observed.
DISCUSSION
The patients in these 3 randomized, placebo-controlled, phase III studies demonstrated significant systemic inflammatory burden, as evidenced by mean disease activity scores and elevated hsCRP levels at baseline. Patients in study 3 (those with nonradiographic axial SpA) required a positive MRI or hsCRP ≥0.6 mg/dl at screening. Results from the week 24 database lock of study 1 showed no treatment effect between ustekinumab and placebo groups across primary and major secondary end points. Based on these results, the sponsor discontinued all 3 studies early. Not all patients in studies 2 and 3 reached the week 24 time point when the studies were discontinued, limiting the extent of those efficacy analyses. The efficacy data available through week 24 of studies 2 and 3 were inconclusive; however, no consistent trends of clinically relevant response were observed among primary and major secondary end points.
Because no formal phase II dose-ranging study was performed, it may be questioned whether the ustekinumab doses studied were too low to achieve clinical response in axial SpA. Median serum ustekinumab concentrations were lower for ASAS40 nonresponders compared with responders receiving the 45 mg dose but were similar for those receiving the 90 mg dose. However, no difference was seen in ASAS20 or ASAS40 response rates across the trough concentration quartiles. Also, studies 1 and 3 showed little difference between doses in the proportions of patients achieving primary and major secondary end points, with the lower dose (45 mg) having a slight numerical advantage in study 3. In study 2, there appeared to be a dose response, but the separation from placebo was limited, and it was not consistent across end points. The hsCRP level in the ustekinumab groups was modestly improved at most time points compared with placebo in studies 1 and 3, but not in study 2, which is in direct contrast to the hint of efficacy in clinical end points seen in study 2. The MRI differences from study 1 favored 90 mg slightly, while 45 mg and placebo were almost equivalent, which contrasts with the lack of clinical benefit demonstrated. Overall, these differences may represent chance variation over the program.
Blocking IL-12/IL-23p40 with ustekinumab has been shown to be efficacious in plaque psoriasis, PsA, and Crohn's disease (14) (15) (16) (17) (18) (19) (20) , in which activation of the IL-23/IL-17 pathway has been reported (31) (32) (33) . Despite both the scientific and clinical rationale for supporting initiation of these phase III studies of ustekinumab in axial SpA, including an open-label study of patients with AS (8) and improvement in PsA patients with physician-reported spondylitis (21) , questions remain as to why ustekinumab was not effective. A recent review highlighted differences in axial disease in AS and PsA, suggesting that spondylitis may be driven by different mechanisms in these 2 diseases (34) . While the immunopathogenesis of axial SpA remains unknown, the interplay of genetics (HLA-B27) with exposure to microbial triggers originating from the gut or skin along with dysregulated innate and adaptive immune responses (the Th17 pathway) has been implicated (35) . Although reports of up-regulation of the Th17 pathway in the spine and joints have been published (36, 37) , there is conflicting evidence regarding dysregulation of the IL-23/ IL-17 axis in the serum of AS patients (38) (39) (40) . In the biomarker subpopulation that was assayed, up-regulation of serum IL-17A was modestly increased only in study 2, but there was no baseline elevation in serum IL-12p70, IL-23, IFNγ, and IL-17A/F in axial SpA patients compared with healthy controls in either study. It is not clear how these findings relate to the lack of clinically relevant efficacy of ustekinumab observed in these studies. It should be noted that serum cytokine levels may not fully represent disease mechanisms present locally in the joints or spine. The therapeutic success of TNF and IL-17 blockers in controlling axial SpA disease activity suggests that the etiology of axial SpA may involve both inflammatory and immune mechanisms. IL-23+ and IL-17+ cells, more so than IL-12+ cells, have been observed in the spine of patients with AS (36) . Blockade of IL-12/IL-23p40 with ustekinumab did not show efficacy in AS, but neutralization of IL-17A is clinically effective (41) , which suggests that the interplay between IL-12, IL-23, and IL-17 is complex in axial SpA and warrants further studies to understand the results. There may be synergistic or opposing effects of inhibiting IL-12 and IL-23 or sources of IL-17 secreted independently of Th17 cells. For example, there is evidence to suggest that innate γδ T cells secrete IL-17 independently of IL-23 to protectively maintain the integrity of the epithelial barrier and prevent excessive permeability after injury (42, 43) . Imbalances in immunopathogenic mechanisms driven by innate lymphoid cell populations may help explain the ineffectiveness of ustekinumab in axial SpA.
AEs reported in these studies were consistent with the known safety profile of ustekinumab (15, 16, 19, 20) . Through week 24, AE rates in the combined ustekinumab groups were similar to those in the placebo group in each study. Infections were the most common type of AE in all 3 studies. Through the end of the study, SAEs were reported by 3.2% of ustekinumab-treated patients, including 3 patients (0.3%) with serious infections. There were no opportunistic infections or malignancies during these studies.
Ustekinumab does not appear to be effective in the treatment of axial SpA. Additional research is needed to better understand the pathogenic mechanisms and the cytokine pathways that manifest as axial SpA. No new safety signals were identified, and the safety profile of ustekinumab in these populations was consistent with that observed in other indications.
